- A dose-response relationship of increased gains in visual acuity (VA) was shown with ascending dose levels of OPT-302
- OPT-302 is also being studied in wet AMD patients
... read more
... read more
Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,